The team announced on Wednesday the isolation of high-purity lead-212 and bismuth-212 nuclides, which are promising for targeted alpha-nuclide therapy (TAT), a new treatment approach for cancers such as ******, pancreatic, and prostate cancer. Currently, the team is exploring the extraction of...